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cense.Abstract Introduction: Hypoandrogenicity is common in men with rheumatoid arthritis who have
lower levels of sex hormones such as testosterone and dehydroepiandrosterone sulphate. The fat tis-
sue hormone leptin is stimulated by tumor necrosis factor alpha (TNF-a), and was found to be asso-
ciated with hypoandrogenicity.
Aim of the work: To study the inter-relation between serum levels of TNF-a, leptin and andro-
gens in early diagnosed RA.
Patients and methods: Serum levels of TNF-a, leptin, testosterone, and (DHEAS) hormones
were measured by ELISA and compared in 40 men with early RA and 30 healthy volunteers.
Results: The mean serum leptin and TNF-a were signiﬁcantly elevated in patients with RA
compared to control group, and both of them were positively correlated with the disease activity
score (DAS28). Sex hormones (testosterone and DHEAS) were signiﬁcantly decreased in male
patients with RA compared to control group, and they were negatively correlated with serum
TNF-a, leptin.com (F. Ismail).
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210 F. Ismail et al.Conclusion: Our data suggest that TNF-a, and leptin may be involved in hypoandrogenicity in
patients with RA and that strategies aimed at interfering with leptin axis could represent innovative
therapeutic tool for hypoandrogenicity in RA.
 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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Rheumatoid arthritis (RA) is more common in females than
males and sex steroid hormones may in part explain this differ-
ence. The female sex predominance in RA may be related to
low androgen levels prior to disease onset since adrenal and
gonadal androgen deﬁciency can trigger inﬂammatory cyto-
kines such as TNF-a and IL-6, that are responsible for the
inﬂammatory response in RA. Alternatively, androgens may
inﬂuence RA risk indirectly through conversion to estradiol
by aromatase or directly by binding to the androgen receptor
and affecting cell proliferation. It was hypothesized that low
total and free testosterone levels and low DHEAS levels mea-
sured before the onset of disease would be associated with an
increased risk of RA in women [1].
RA may be accompanied with sexual growth retardation
with different degrees and it is also accompanied with an
increased secretion of TNF-a and leptin. Tumor necrosis fac-
tor alpha (TNF-a) is among the cytokines that play a major
role in the inﬂammatory process of rheumatic diseases. Its
inhibition leads to substantial improvement in clinical signs
and symptoms in a majority of patients [2]. TNF-a was found
to be particularly increased in RA synovitis, and was able to
markedly stimulate the aromatase activity in peripheral tissues
and, therefore, induce the peripheral metabolism from andro-
gens to estrogens. The effects of TNF blockers (and generally
of anticytokine agents) on peripheral sex hormone levels seem
to be exerted in a faster way at the level of the RA synovial tis-
sue (before any inﬂuence on serum levels) where they seem to
block the conversion from androgens (anti-inﬂammatory) to
estrogens (proinﬂammatory) induced by aromatase [3].
The study of leptin has shown the intricate network that
links nutrition, metabolism and immune homeostasis. Leptin
is mainly produced by the adipose tissue in proportion to body
mass. Although an important role of leptin is to regulate body
weight, recent evidence has indicated that leptin is much more
than a fat-0-stat sensor, leptin exerts peripheral functions,
including regulation of endocrine function, reproduction and
immunity. Several studies have shown that circulating levels
of leptin increase during infection and inﬂammation, suggest-
ing that leptin is part of the immune response and host defense
mechanisms [4].
This study aimed at investigating serum TNF-a and leptin
levels in relation to serum concentrations of androgens in pa-
tients with early diagnosed RA.2. Patients and methods
2.1. Patients
Forty male patients fulﬁlling American College of Rheumatol-
ogy (ACR) criteria for a diagnosis of RA [5], and thirty healthy
volunteers served as controls were studied. The patients wereattending the Rheumatology Department at El-Minia Univer-
sity Hospital in the period of 13 months. The patients had
early RA where disease modifying anti rheumatic drugs
(DMARDs) and/or glucocorticoids had not been introduced
when the examinations were carried out. General and locomo-
tor examination were done to detect articular and extra-
articular involvement, swollen and tender joint counts of the
RA patients were recorded and the disease activity score
(DAS28) [6] were used to assess disease activity. Patients were
assessed for symptoms or signs for hypoandrogenicity
(reduced libido, reduced muscle mass, and strength, depressed
mood, decreased energy or vitality, increased fatigue, incom-
plete sexual development, breast discomfort, gynaecomastia,
poor concentration and memory, and menopausal – type hot
ﬂushes). Subjects with diabetes mellitus, hypertension, or any
other systemic disease and malignancy were excluded from
the study. BMI is calculated as weight in kilograms divided
by height in square meters. BMI < 25 kg/m2 is considered
normal, from 25-30 overweight, from 30 to 40 obese, and
>40 is considered morbid obesity [7,8]. The study was ethi-
cally approved by local ethical committee.
2.2. Methods
Radiographic evaluation: Plain X-Ray was done for hands and
wrists, and graded by (Larsen scale) [9] the presence of ero-
sions was determined also using Ultrasonography (US).
Laboratory investigations included: Complete blood count,
Erythrocyte sedimentation rate, C-reactive protein level, com-
plete urine analysis, liver function tests, renal function tests,
and presence of rheumatoid factor were measured by standard
techniques.
3. Determination of serum leptin, TNF-a, and Androgens
3.1. Collection and preparation of the samples
Venous blood samples were collected from every subject by
sterile venipuncture on the same day of history taking and clin-
ical examination, 2 milliliters of blood was taken for ESR
determination. Separated serum was kept frozen at -80 C till
the time of estimation of serum TNF-a, leptin, testosterone
and dehydroepiandrosterone sulphate.
3.2. Determination of serum leptin
Kits were used for determination were (Bio Vender –Laborato-
ni medicina, a.s. Czech Republic) .Leptin ELISA Clinical
Range, standards, quality controls and samples are incubated
in micro plate wells pre-coated with polyclonal anti-human
leptin antibody. After 60 minutes incubation and washing,
polyclonal anti-human leptin antibody, conjugated with horse-
radish peroxidase (HRP) is added to the wells and incubated
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ing step, the remaining HRP conjugate is allowed to react with
the substrate solution (TMB). The reaction is stopped by addi-
tion of acidic solution and absorbance of the resulting yellow
product is measured. The absorbance is proportional to the
concentration of leptin. A standard curve is constructed by
plotting absorbance values against concentrations of stan-
dards, and concentrations of unknown samples are determined
using this standard curve [10].
3.3. Determination of serum TNF-a
Kits were used for determination were (BioVendor-Laborator-
ni medicina, a.s. Czech Republic). An anti-human TNF-a
coating antibody is adsorbed onto microwells. Human
TNF-a present in the sample or standard binds to antibodies
adsorbed to the microwells. A biotin-conjugated anti-human
TNF-a antibody is added and binds to human TNF-a cap-
tured by the ﬁrst antibody. Following incubation unbound
biotin-conjugated anti-human TNF-a antibody is removed
during a wash step. Streptavidin-HRP is added and binds to
the biotin conjugated anti-human TNF-a antibody. Following
incubation unbound Streptavidin-HRP is removed during a
wash step, and substrate solution reactive with HRP is added
to the wells. A coloured product is formed in proportion to the
amount of human TNF-a present in the sample or standard.
The reaction is terminated by addition of acid and absorbance
is measured at 450 nm. A standard curve is prepared from 7
human TNF-a standard dilution [11].
3.4. Determination of serum Androgens
Measurements were done according to instructions illustrated
in the kits (BioVendor-Laboratorni medicina, a.s. Czech
Republic) for DHEAS and total testosterone and (GenWay
Biotech, Inc. San Diego, USA) for free testosterone.
Statistical analyses were performed using SPSS version 10.0
(SPSS, Chicago, IL). Continuous data are expressed as
mean ± standard deviation (SD). The differences among cases
and controls were determined by independent sample t-test for
continuous data. The correlation of leptin with TNF-a, andTable 1 Demographic, clinical, and laboratory data in RA patients
RA (n= 40) (me
Age 32.83 ± 7.39
Disease Duration (ms.) 9.28 ± 2.32
Rheumatoid nodules No.(%) 4 (10%)
No. of swollen Joints 3.9 ± 2.8
ESR 30.67 ± 14.10
RF +ve No (%) 26 (65%)
DAS28 3.87 ± 1.08
BMI 23.30 ± 1.06
Leptin (ng/ml) 32.40 ± 3.92
TNF-a (pg/ml) 92.93 ± 20.82
Total testosterone (ng/ml) 1.56 ± 0.50
Free testosterone (pg/ml) 8.73 ± 4.12
DHEAS (lg/dl) 68.23 ± 12.97
ESR (erythrocyte sedimentation rate), DAS28 (disease activity score), RF
factor alpha), DHEAS (dehydroepiandrosteron sulphate).
* Signiﬁcant difference from Control at p< 0.05.between leptin and TNF-a and serum androgens was calcu-
lated using Spearman correlation test. Statistical signiﬁcance
was set at p< 0.05.4. Results
4.1. Characteristics of the patients with RA and controls
Forty consecutive male patients with early RA were recruited
for the study by a rheumatologist from a rheumatology outpa-
tient service, with a mean age of 32.83 ± 7.39 years. The mean
duration of disease was 9.28 ± 2.32 months. Rheumatoid
factor was positive in 26 patients (65%), DAS 28 was
3.87 ± 1.08. A control group of 30 healthy male subjects with
a mean age of 34.17 ± 7.81 years no signiﬁcant differences
between age and BMI between patients and controls, no symp-
toms or signs of hypoandrogenicity were detected (Table 1).
4.2. Serum concentrations of leptin, TNF-a, testosterone and
dehyroepiandrosterone sulphate
The mean serum leptin were signiﬁcantly elevated in patients
with RA compared to control group (32.40 ± 3.92 and
21.52 ± 2.0 ng/ml, respectively). Also the mean serum TNF-
a were signiﬁcantly elevated in patients with RA compared
to control group (92.93 ± 20.82 and 14.73 ± 2.09 pg/ml,
respectively) (Fig. 1). On the contrary DHEAS were signiﬁ-
cantly decreased in patients with RA compared to control
group 68.23 ± 12.97 and 213.13 ± 62.98 lg/dl, respectively.
Regarding the total testosterone it was 1.56 ± 0.50 and
6.89 ± 1.87 ng/ml in RA and control respectively and the free
testosterone 8.73 ± 4.12 and 30.97 ± 8.50 pg/ml, respectively
(Table 1).
4.3. Correlations between serum leptin, TNF-a with the DAS 28
score
Serum levels of leptin and TNF-a were positively correlated
with the disease activity score (r 0.58, p< 0.001 and r 0.62,
p< 0.001, respectively) (Figs. 2,3).and controls.
an ± SD) Control (n= 30) (mean ± SD)
34.17 ± 7.81
–
–
–
–
–
–
24.19 ± 1.57
21.52 ± 2.0*
14.73 ± 2.09*
6.89 ± 1.87*
30.97 ± 8.50*
213.13 ± 62.98*
(rheumatoid factor), BMI (body mass index), TNF-(tumor necrosis
Figure 1 Box plot showing the comparison of the serum leptin and TNF-a level in both patients and controls. *Signiﬁcant difference
from Control at p< 0.05.
Figure 2 Correlation studies between the serum leptin level with (A) DAS28, (B) DHEAS, (C) total and (D) free testosterone in RA
patients.
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Figure 3 Correlation studies between the serum TNF-a level with (A) DAS28, (B) DHEAS, (C) total and (D) free testosterone in RA
patients.
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There was a negative correlation between serum leptin and
serum androgens (DHEAS, total testosterone and free testos-
terone) (r 0.42, p 0.007; r 0.48, p 0.002 and r 0.048, p
0.771, respectively) (Fig. 2).
There was a negative correlation between serum TNF-a
and serum androgens (DHEAS, total testosterone, and free
testosterone). (r 0.58, p< 0.001; r 0.54, p< 0.001 and rTable 2 Correlations between serum leptin, TNF-a, DAS and
androgens.
Serum leptin Serum TNF-a
r p r p
DAS28 0.58* <0.001 0.62* <0.001
DHEAS 0.42* 0.007 0.58* <0.001
Testosterone (total) 0.48* 0.002 0.54* <0.001
Testosterone (free) 0.048 0.771 0.34* 0.031
Serum leptin 0.49 0.002*
Serum TNF-a 0.49* 0.002
DAS28 (disease activity score), DHEAS (dehydroepiandrosteron
sulphate), TNF-(tumor necrosis factor alpha).
* Signiﬁcant at p< 0.05.0.34, p 0.031, respectively) (Fig. 3). Correlation results of
the studied parameters are shown in Table 2.
5. Discussion
Chronic inﬂammatory diseases in human such as rheumatoid
arthritis are characterized by a dramatic decrease of serum lev-
els of adrenal androgens. Treatment with dehyroepiandroster-
one (DHEA) as the starting point of androgen conversion has
been proved to be a therapeutic alternative in systemic lupus
erythematosus and possibly in patients with chronic inﬂamma-
tory bowel disease. This indicates that androgens have anti-
inﬂammatory inﬂuence, which is switched off during long term
systemic inﬂammatory responses [12].
The fat tissue hormone leptin may be an important link be-
tween hyperandrogenicity and obesity. A large number of cell
types can produce this hormone (for example white adipose
tissue cells, endothelial cells, T-lymphocytes, bone marrow
cells, spleen cells, platelets, etc.) [13]. The role of leptin for food
intake (inhibitory effect) and metabolic and endocrine func-
tions has been extensively described. However, leptin also reg-
ulates immunity, inﬂammation, haematopoiesis and adrenal
androgen secretion [14].
Tumor necrosis factor alpha (TNF-a) is one of the most
common pro-inﬂammatory cytokines responsible for various
inﬂammatory disorders. It plays an important role in the
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other autoimmune disease conditions. TNF-a is a multifunc-
tional cytokine involved in inﬂammation, apoptosis, cell
survival and immunity acting via two receptors TNF-R55
and TNF-R75 [3,4]. It causes severe damage when produced
in excess amount and is also a strong inducer of other pro-
inﬂammatory cytokines such as IL-1b, IL-6, and IL-8 [15].
This study aimed at investigating serum TNF-a and leptin lev-
els in relation to serum concentrations of adrenal androgens in
patients with RA.
In the current study concentrations of leptin were signiﬁ-
cantly higher in patients with RA compared with control sub-
jects and the increase in leptin concentration was positively
correlated with the disease activity. Concentrations of leptin
did not differ signiﬁcantly among patients with seropositive
and seronegative RA. These results are in consistent with other
studies [14,16] and are contradictory with others [17,18]. The
reasons for this discrepancy between our study and these stud-
ies may be related to the effects of medications on their
patients and the higher body mass index in their study patients
compared to ours.
This study showed a signiﬁcant increase in TNF-a in
patients with RA which was positively correlated with the dis-
ease activity. Also, there was a positive correlation between
levels of leptin and levels of TNF-a in patient with RA. These
results are in consistent with another study [19] that reported
that the chronic inﬂammation of the joints in case of RA leads
to diffuse thickening and hyperplasia of the synovium. It is
inﬁltered with numerous inﬂammatory cells that produce sev-
eral proinﬂammatory cytokines including interleukin (IL)-6
and TNF-a. These proinﬂammatory cytokines in turn increase
circulating leptin concentrations [20]. It has been reported that
TNF-a can act directly on adipocytes to stimulate leptin secre-
tion, it was explained that this hyperleptinemia is likely medi-
ated via transcriptional activation of the leptin gene which
leads to subsequent increase in leptin gene expression [20,21].
The results of this study showed that RA patients had a
lower androgen level than controls and this result is in agree-
ment with another study [22] that concluded that during a
chronic inﬂammatory process like active RA, levels of both
serum testosterone and, in particular, serum DHEAS become
lower. Since testosterone and its precursors DHEAS and
DHEA have anti-inﬂammatory properties, the decline in levels
of these hormones further supports the pro-inﬂammatory pro-
cess. Furthermore, others [23] found that in early RA, current
inﬂammation seemed to affect the hypophyseal gonadal axis
(HPG axis), mainly at the gonadal rather than the hypotha-
lamic-pituitary level, and a prospective studies are indicated
to determine if low HPG activity may be a cause rather than
a consequence of a chronic inﬂammatory state.
In the current study serum testosterone and DHEAS levels
are inversely correlated with RA activity and these results are
in agreement with the results of Cutolo [24] who found that
serum testosterone levels are inversely correlated with RA
activity and dehydroepiandrosterone sulfate (DHEAS) plasma
levels are inversely correlated with both disease duration and
clinical severity in patients already affected by active RA.
The results of this work showed that there were negative
correlation between serum leptin levels and the levels of se-
creted androgens in the patients of RA. These results are in
consistent with other results in bovine adrenocortical cells
demonstrated that leptin induced inhibition of 17 a–hydroxy-lase P450 mRNA expression which is the key enzyme for
androgen production [25]. The same study demonstrated that
leptin induced inhibition of P450c21 and P450scc mRNA
expression. Moreover, it has been reported that a similar inhib-
itory inﬂuence of leptin exists on human adrenocortical cells
[26]. The concept that leptin induced inhibition of an impor-
tant enzyme step of the 17/20-lyase (2nd reaction of the
P450c17) in patients with RA has been supported [12].
We found a negative correlation between testosterone, and
DHEAS levels and TNF-a and this result go in hand with the
results of Emnestam and coworkers [22] who concluded that in
the adrenal and gonadal glands, the loss of DHEA and
DHEAS is attributed to a synthetic blockade of the second
step of the enzyme P450c17, again induced by inﬂammatory
cytokines such as IL1b and TNF.
From the previous data we found that in patients with RA
there were signiﬁcant increases in serum leptin levels compared
to controls which may be related to the increase in the level of
TNF-a. Increase in both serum leptin and TNF-a are associ-
ated with a signiﬁcant decrease in serum androgens. All these
data constitute a strong ring which if can be broken at any
point may improve the progress of the rheumatic disease.
Furthermore, understanding the complex relation between
inﬂammatory cytokines and hormones may contribute to the
development of new therapeutic targets for clinical interven-
tion in RA. Hypoandrogenism is present in male patients with
RA and may be relevant in disease pathogenesis. However,
whether these hormonal abnormalities are intrinsic to RA or
the consequence of any non-speciﬁc disorders cannot be distin-
guished from the current data. Further studies involving a
larger number of subjects and inclusion of other disease con-
trols are needed.
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